Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Varivax (Merck & Co).

Taff Jones1

  • 1Intellivax International Inc, Ville St-Laurent, Quebec, Canada. tjones@intellivax.com

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Varivax is a live-attenuated varicella vaccine that prevents chickenpox. A second-generation vaccine, Varivax II, offers improved refrigerator stability while maintaining the same safety and efficacy profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Vaccine·2012
Same author

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

PloS one·2010
Same author

Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000)·2010
Same author

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

Current opinion in molecular therapeutics·2009
Same author

IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.

Current opinion in molecular therapeutics·2009
Same author

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Current opinion in molecular therapeutics·2008

Area of Science:

  • Immunology
  • Vaccinology

Background:

  • Varivax is a live-attenuated varicella vaccine developed by Merck & Co. in the US.
  • It utilizes the Oka strain of the varicella virus, licensed from Japan's Biken Institute.
  • Merck was also developing Varivax for adult herpes zoster infection by June 2001.

Purpose of the Study:

  • To detail the development, approval, and market introduction of the Varivax vaccine.
  • To highlight recommendations for Varivax administration alongside other childhood vaccines.
  • To introduce the second-generation Varivax II vaccine and its advantages.

Main Methods:

  • The development of Varivax involved licensing the Oka strain of the varicella virus.
  • Post-marketing studies were required by the FDA for its approval in March 1995.

Related Experiment Videos

  • Varivax II was developed with an emphasis on refrigerator stability.

    • Main Results:

    • Varivax received FDA approval in March 1995.
    • Sales reached US $60 million by the end of Q3 1995.
    • Varivax II was launched in June 2000 for individuals 12 months and older.

    Conclusions:

    • Varivax is an effective vaccine for preventing chickenpox.
    • Recommendations support co-administration with measles, mumps, and rubella vaccine for children.
    • Varivax II provides enhanced stability for chickenpox vaccination.